戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 clized peptides, a resemblance heightened by heterologous prime-boost.
2 s in successive immunization campaigns or as heterologous prime-boost agents.
3 y of these constructs was evaluated using a "heterologous prime-boost" approach consisting of mucosal
4 Completing the serial immunization steps for heterologous prime-boost-boost can be lengthy, leaving t
5                                              Heterologous prime-boost-boost immunization has been sho
6                   These results suggest that heterologous prime-boost combinations have distinct immu
7 sing vaccines against bovine TB are based on heterologous prime-boost combinations that include BCG,
8                                              Heterologous prime-boosting has emerged as a powerful va
9                              Here, we used a heterologous prime-boost immunization approach using a c
10                                         Such heterologous prime-boost immunization approaches may pro
11                                   AdCh63-MVA heterologous prime-boost immunization induces strong and
12                                              Heterologous prime-boost immunization strategies can evo
13              We also describe homologous and heterologous prime-boost immunization strategies using n
14 vel vaccine were assessed in mice by using a heterologous prime-boost immunization strategy and compa
15                                              Heterologous prime-boost immunization with plasmid DNA a
16 re examined by using multiple homologous and heterologous prime/boost immunization regimens in order
17                                          The heterologous prime/boost immunization regimens that invo
18 ntrast, Mamu-A*01+ monkeys that had received heterologous prime/boost immunizations prior to challeng
19 ors, the possibility has arisen of employing heterologous prime/boost immunizations using diverse mem
20                Recent clinical trials of new heterologous prime-boost malaria vaccine regimens using
21                                              Heterologous prime-boost may provide a more effective va
22  a single immunization or in a homologous or heterologous prime-boost modality.
23 s shown that vaccination strategies based on heterologous prime-boost protocols using Mycobacterium b
24            ChAd63-MVA AMA1 administered in a heterologous prime-boost regime was shown to be safe and
25 used to vaccinate rhesus macaques with a new heterologous prime-boost regimen designed to optimize in
26                These vectors, when used in a heterologous prime-boost regimen in BALB/c mice, are cap
27                  In contrast, an accelerated heterologous prime-boost regimen involving administratio
28 hrocytic vaccine will likely be based upon a heterologous prime-boost regimen that induces both appro
29 ted its immunogenicity early in life using a heterologous prime-boost regimen.
30             In this study, we show that such heterologous prime boost regimens based on E1-deleted ad
31 rime AIDS virus-specific T-cell responses in heterologous prime boost regimens.
32                                        Thus, heterologous prime-boost regimens boost CD4(+) as well a
33 Moreover, anatomic separation strategies and heterologous prime-boost regimens generated codominant r
34 his study supports the rationale for testing heterologous prime-boost regimens in humans.
35 to evaluate the safety and immunogenicity of heterologous prime-boost regimens, with a New York vacci
36 3-specific CTLs can, however, be expanded by heterologous prime-boost regimens.
37 serotype Ad vectors than with Ad5 vectors in heterologous prime-boost regimens.
38 nses when administered with rVSVN4CT1gag1 in heterologous prime-boost regimens.
39 f cytotoxic-T-lymphocyte responses have been heterologous prime/boost regimens employing a plasmid DN
40                                              Heterologous prime/boost regimens have the potential for
41                                              Heterologous "prime-boost" regimens that involve priming
42  future clinical trials testing vector-based heterologous prime-boost strategies.
43 nds in vaccination strategies, particularly "heterologous prime-boost" strategies against tumors, and
44 ed MV vaccines to be used early in life in a heterologous prime-boost strategy.
45 aepithelial neoplasia were vaccinated with a heterologous prime/boost strategy consisting of gene gun
46  the current live attenuated MV vaccine in a heterologous prime-boost to protect against measles earl
47                                              Heterologous prime boost vaccination minimizes contracti
48                         This study exploited heterologous prime boost vaccination to discover paramet
49                                              Heterologous prime-boost vaccination has been shown to b
50                                         Only heterologous prime-boost vaccination induced modest cros
51                          Here we show that a heterologous prime-boost vaccination regime of DNA eithe
52                   These results suggest that heterologous prime-boost vaccination regimens enhance im
53                                              Heterologous prime-boost vaccination results in increase
54                 In this study, we employed a heterologous prime-boost vaccination strategy comprising
55         This study reports the efficacy of a heterologous prime-boost vaccination using DNA and vacci
56                   We explored the concept of heterologous prime/boost vaccination using 2 therapeutic
57                                          The heterologous prime-boost vaccine regimen used recombinan
58                                              Heterologous prime-boost vaccine regimens induced partic
59                 Our results demonstrate that heterologous prime-boost vaccine regimens with alternati
60 rhesus monkeys and can be combined as potent heterologous prime-boost vaccine regimens.
61                    ChAd63-MVA is a promising heterologous prime-boost vaccine strategy that could be
62 at CD4(+) and CD8(+) T cell responses with a heterologous prime/boost vaccine approach could induce l
63                                              Heterologous prime-boost with the viral vectors simian a
64                                              Heterologous prime/boost with Cy/GVAX and CRS-207 extend

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。